Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - A clinical research center study

被引:85
作者
vanderPoll, T
Barber, AE
Coyle, SM
Lowry, SF
机构
[1] CORNELL UNIV MED COLL, DEPT SURG, LAB SURG METAB, NEW YORK, NY 10021 USA
[2] UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS
[3] TEXAS TECH UNIV, HLTH SCI CTR, DEPT SURG, LUBBOCK, TX 79430 USA
关键词
D O I
10.1210/jc.81.10.3604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypercortisolemia directly before the administration of endotoxin (LPS) to normal humans completely prevents the release of the proinflammatory cytokine tumor necrosis factor, whereas hypercortisolemia 12 h to 7 days before the injection of LPS is associated with enhanced tumor necrosis factor release. To determine the effect of elevated cortisol levels on the secretion of the antiinflammatory cytokine interleukin-10 (IL-10), 23 healthy men were given iv LPS (lot EC-5; 2 ng/kg) done or in combination with a continuous iv infusion of hydrocortisone (3 mu g/kg . min) for 6 h immediately before or 6, 12, or 144 h before LPS injection. LPS induced a monophasic increase in plasma IL-10 concentrations that peaked after 2 h (162 +/- 27 pg/mL; P < 0.0001). In subjects who were infused with hydrocortisone directly before LPS administration, IL-10 concentrations were much higher (1784 +/- 331 pg/mL; P < 0.0001 vs. LPS only), whereas hypercortisolemia 6, 12, or 144 h before LPS injection did not influence LPS-induced IL-10 levels. In human whole blood in vitro, hydrocortisone caused a dose-dependent reduction of LPS-induced IL-10 levels. Further, hydrocortisone reversed the increase in IL-10 concentrations by epinephrine in LPS-stimulated whole blood. Stimulation of IL-10 release may contribute to the antiinflammatory properties of glucocorticoids.
引用
收藏
页码:3604 / 3606
页数:3
相关论文
共 16 条
[1]   GLUCOCORTICOIDS SUPPRESS INTERLEUKIN-1 RECEPTOR ANTAGONIST SYNTHESIS FOLLOWING INDUCTION BY ENDOTOXIN [J].
ARZT, E ;
SAUER, J ;
POLLMACHER, T ;
LABEUR, M ;
HOLSBOER, F ;
REUL, JMHM ;
STALLA, GK .
ENDOCRINOLOGY, 1994, 134 (02) :672-677
[2]   INFLUENCE OF HYPERCORTISOLEMIA ON SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II AND INTERLEUKIN-1 RECEPTOR ANTAGONIST RESPONSES TO ENDOTOXIN IN HUMAN-BEINGS [J].
BARBER, AE ;
COYLE, SM ;
FISCHER, E ;
SMITH, C ;
VANDERPOLL, T ;
SHIRES, T ;
LOWRY, SF .
SURGERY, 1995, 118 (02) :406-411
[3]  
BARBER AE, 1993, J IMMUNOL, V150, P1999
[4]   CONTROL OF CACHECTIN (TUMOR-NECROSIS-FACTOR) SYNTHESIS - MECHANISMS OF ENDOTOXIN RESISTANCE [J].
BEUTLER, B ;
KROCHIN, N ;
MILSARK, IW ;
LUEDKE, C ;
CERAMI, A .
SCIENCE, 1986, 232 (4753) :977-980
[5]  
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
[6]   HORMONAL-CONTROL OF METABOLISM IN TRAUMA AND SEPSIS [J].
FRAYN, KN .
CLINICAL ENDOCRINOLOGY, 1986, 24 (05) :577-599
[7]   INTERLEUKIN-10 REDUCES THE RELEASE OF TUMOR-NECROSIS-FACTOR AND PREVENTS LETHALITY IN EXPERIMENTAL ENDOTOXEMIA [J].
GERARD, C ;
BRUYNS, C ;
MARCHANT, A ;
ABRAMOWICZ, D ;
VANDENABEELE, P ;
DELVAUX, A ;
FIERS, W ;
GOLDMAN, M ;
VELU, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :547-550
[8]   INTERLEUKIN-10 PROTECTS MICE FROM LETHAL ENDOTOXEMIA [J].
HOWARD, M ;
MUCHAMUEL, T ;
ANDRADE, S ;
MENON, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :1205-1208
[9]  
MALEFYT RD, 1991, J EXP MED, V174, P1209
[10]   INTERLEUKIN-10 CONTROLS INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR PRODUCTION DURING EXPERIMENTAL ENDOTOXEMIA [J].
MARCHANT, A ;
BRUYNS, C ;
VANDENABEELE, P ;
DUCARME, M ;
GERARD, C ;
DELVAUX, A ;
DEGROOTE, D ;
ABRAMOWICZ, D ;
VELU, T ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (05) :1167-1171